Search

Displaying results 4081 - 4090 of 5895 in total
  1. Drug

    Ethyl butyrate

    go.drugbank.com/drugs/DB15454
    Experimental

    Ethyl butyrate is under investigation in clinical trial NCT03202342 (fMRI of Hypothalamic Responses to Taste, Temperature and Glucose).

  2. Drug

    Buprenorphine hemiadipate

    go.drugbank.com/drugs/DB16117
    Investigational

    Buprenorphine hemiadipate is under investigation in clinical trial NCT01582347 (Transfer of Subjects From Subutex/suboxone to RBP-6300).

  3. Drug

    Solrikitug

    go.drugbank.com/drugs/DB19301
    Investigational

    Solrikitug is under investigation in clinical trial NCT06496607 (A Study to Evaluate Solriktug in Adult Participants With Asthma).

  4. Drug

    ATL1101

    go.drugbank.com/drugs/DB05023
    Experimental

    ATL1101 is being developed as a cream for the topical treatment of mild to moderate cases of psoriasis. … ATL1101 is a second-generation antisense drug designed to block the synthesis of the IGF-1 receptor, a protein involved in the regulation of cell overgrowth in psoriasis.

  5. Drug

    VB2-011

    go.drugbank.com/drugs/DB05411
    Experimental

    According to some preclinical studies, it has a potential to inhibit tumour growth in various cancers including lymphoma and melanoma.

  6. Drug

    Sparfosic acid

    go.drugbank.com/drugs/DB03459
    Experimental

    This substance is known to target aspartate carbamoyltransferase catalytic chain and CAD protein. … This compound belongs to the n-acyl-alpha amino acids. These are compounds containing an alpha amino acid which bears an acyl group at the terminal nitrogen atom.

  7. Drug

    IGN301

    go.drugbank.com/drugs/DB05117
    Experimental

    IGN301 is a cancer vaccine based on an anti-idiotypic antibody which provokes an immune response to Lewis Y.

  8. Drug

    ALKS 27

    go.drugbank.com/drugs/DB05752
    Experimental

    Study showed that ALKS 27 was well-tolerated over a wide dose range, with no dose-limited effects observed.

  9. Drug

    EHT899

    go.drugbank.com/drugs/DB05108
    Experimental

    EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection. … It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and decrease in viral load.

  10. Drug

    VY-HTT01

    go.drugbank.com/drugs/DB16999
    Investigational

    VY-HTT01 is a gene therapy designed to reduce the expression of huntingtin, thereby altering disease progression. … VY-HTT01 is comprised of an adeno-associated virus capsid (AAV1) and a proprietary transgene that harnesses the canonical RNA interference pathway to selectively knock down levels of HTT mRNA.